Profile data is unavailable for this security.
About the company
Ocean Biomedical, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing therapeutic products in oncology, fibrosis, infectious diseases, and inflammation. The Company helps to accelerates the development and commercialization of assets from research universities and medical centers. In oncology, it is engaged in developing a mono-specific and two bi-specific humanized monoclonal antibodies (mAb), product candidates targeting Chi3l1 for the treatment of non-small cell lung cancer (NSCLC), and of glioblastoma multiforme (GBM). It offers three product candidates based on the novel target discoveries: a malaria vaccine candidate targeting either or both of PfSEA-1, and parasite antigen PfGARP, which is referred to as its ODA-570 candidate; a humanized mAb malaria therapeutic candidate targeting PfGARP, which is referred to as ODA-611 candidate, and a small molecule malaria therapeutic candidate targeting PfGARP, which is referred to as ODA-579 candidate.
- Revenue in USD (TTM)0.00
- Net income in USD-98.59m
- Incorporated2021
- Employees9.00
- LocationOcean Biomedical Inc515 Madison Ave Suite 8078NEW YORK 10022United StatesUSA
- Phone+1 (646) 908-2658
- Websitehttps://www.oceanbiomedical.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ibio Inc | 175.00k | -14.36m | 22.39m | 16.00 | -- | 1.19 | -- | 127.93 | -3.97 | -6.65 | 0.0307 | 2.06 | 0.0056 | -- | -- | 10,937.50 | -46.17 | -27.69 | -75.53 | -33.13 | -- | -- | -8,204.57 | -1,862.11 | -- | -- | 0.0736 | -- | -- | -35.52 | 47.31 | -- | -26.66 | -- |
| Tempest Therapeutics Inc | 0.00 | -35.52m | 22.53m | 17.00 | -- | 2.07 | -- | -- | -1.57 | -1.57 | 0.00 | 0.4313 | 0.00 | -- | -- | 0.00 | -122.85 | -57.10 | -195.00 | -71.20 | -- | -- | -- | -- | -- | -- | 0.426 | -- | -- | -- | 17.41 | -- | 36.40 | -- |
| Forte Biosciences Inc | 0.00 | -34.20m | 22.84m | 11.00 | -- | 2.44 | -- | -- | -20.00 | -20.00 | 0.00 | 6.42 | 0.00 | -- | -- | 0.00 | -103.90 | -72.06 | -137.40 | -82.27 | -- | -- | -- | -491,850.00 | -- | -- | 0.00 | -- | -- | -- | -126.79 | -- | -46.29 | -- |
| Cadrenal Therapeutics Inc | 0.00 | -7.61m | 23.24m | 4.00 | -- | 5.07 | -- | -- | -7.05 | -7.05 | 0.00 | 2.76 | 0.00 | -- | -- | 0.00 | -108.76 | -- | -125.13 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.47 | -- | -- | -- |
| Exicure Inc | 500.00k | -4.01m | 23.59m | 6.00 | -- | 15.27 | -- | 47.18 | -2.26 | -2.26 | 0.282 | 0.7112 | 0.0424 | -- | 0.4852 | 83,333.34 | -33.98 | -41.52 | -45.26 | -55.78 | -- | -- | -801.40 | -290.95 | -- | -- | 0.00 | -- | -100.00 | -- | -555.07 | -- | -- | -- |
| Lisata Therapeutics Inc | 0.00 | -20.74m | 23.66m | 25.00 | -- | 0.7023 | -- | -- | -2.51 | -2.51 | 0.00 | 4.05 | 0.00 | -- | -- | 0.00 | -43.08 | -45.97 | -47.69 | -50.47 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 61.57 | -- | -- | -- |
| Ocean Biomedical Inc | 0.00 | -98.59m | 24.70m | 9.00 | -- | -- | -- | -- | -3.01 | -3.01 | 0.00 | -2.21 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -0.2443 | -- | -- | -- | -- | 72.16 | -- | -- | -- |
| Athira Pharma Inc | 0.00 | -109.22m | 25.34m | 65.00 | -- | 0.4426 | -- | -- | -2.85 | -2.85 | 0.00 | 1.49 | 0.00 | -- | -- | 0.00 | -80.62 | -30.73 | -101.80 | -32.46 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -23.04 | -- | -- | -- |
| Geovax Labs Inc | 3.09m | -24.32m | 25.48m | 17.00 | -- | 2.73 | -- | 8.24 | -9.21 | -9.21 | 0.9299 | 0.9878 | 0.2263 | -- | -- | 181,774.10 | -178.10 | -108.34 | -276.02 | -147.24 | -- | -- | -787.08 | -1,842.93 | -- | -- | 0.00 | -- | -100.00 | -- | -85.20 | -- | -- | -- |
| Equillium Inc | 45.91m | -4.62m | 25.51m | 45.00 | -- | 1.10 | -- | 0.5555 | -0.1316 | -0.1316 | 1.29 | 0.6543 | 1.02 | -- | 10.46 | 1,043,500.00 | -10.29 | -46.81 | -18.30 | -57.36 | -- | -- | -10.05 | -328.35 | -- | -- | 0.00 | -- | 128.97 | -- | 78.64 | -- | 7.48 | -- |
| ABPRO Holdings Inc | 0.00 | 4.29m | 25.57m | -- | 22.79 | 1.62 | -- | -- | 0.1396 | 0.1396 | 0.00 | 1.97 | 0.00 | -- | -- | -- | 2.48 | -- | 2.53 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 49,648.60 | -- | -- | -- |
| Marker Therapeutics Inc | 5.40m | -9.63m | 26.34m | 8.00 | -- | 3.53 | -- | 4.88 | -1.08 | -1.09 | 0.6057 | 0.837 | 0.355 | -- | 13.04 | 674,481.30 | -63.39 | -53.74 | -79.76 | -62.25 | -- | -- | -178.54 | -1,438.71 | -- | -- | 0.00 | -- | -5.76 | 74.27 | 28.97 | -- | -- | -- |
| Lipocine Inc | 7.92m | -4.06m | 26.74m | 17.00 | -- | 1.40 | -- | 3.38 | -0.7626 | -0.7626 | 1.48 | 3.57 | 0.3486 | -- | 119.56 | 466,054.70 | -17.85 | -39.32 | -19.49 | -45.87 | -- | -- | -51.19 | -442.26 | -- | -- | 0.00 | -- | -670.16 | -- | -51.99 | -- | -- | -- |
| DURECT Corp | 8.59m | -17.07m | 26.77m | 45.00 | -- | 22.00 | -- | 3.12 | -0.5556 | -0.5556 | 0.2813 | 0.0392 | 0.2181 | 0.7417 | 9.05 | 148,172.40 | -43.33 | -37.34 | -156.35 | -53.44 | 78.87 | 91.83 | -198.62 | -139.11 | 0.5963 | -24.30 | 0.8958 | -- | -55.67 | -10.96 | 21.82 | -- | -10.98 | -- |
Data as of Nov 21 2024. Currency figures normalised to Ocean Biomedical Inc's reporting currency: US Dollar USD
10.24%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Polar Asset Management Partners, Inc.as of 30 Sep 2024 | 2.69m | 7.76% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 399.88k | 1.15% |
| Geode Capital Management LLCas of 30 Sep 2024 | 140.99k | 0.41% |
| Millennium Management LLCas of 30 Sep 2024 | 127.56k | 0.37% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 59.12k | 0.17% |
| Citadel Securities LLCas of 30 Sep 2024 | 32.91k | 0.10% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 32.80k | 0.10% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 2024 | 26.78k | 0.08% |
| BMO Asset Management, Inc.as of 30 Sep 2024 | 20.00k | 0.06% |
| XTX Markets LLCas of 30 Sep 2024 | 18.56k | 0.05% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
